New Method for Newborn Screening of Sickle Cell Disease
Author Information
Author(s): Renoux Céline, Roland Estelle, Ruet Séverine, Zouaghi Sarah, Michel Marie, Joly Philippe, Feray Cécile, Zhao Fanny, Gavanier Déborah, Gaucherand Pascal, Roumieu Fanny, Cannas Giovanna, Merazga Salima, Connes Philippe, Renom Gilles, Massardier Jérôme, Cheillan David, Lobitz Stephan
Primary Institution: Laboratoire de Biologie Médicale Multi-Sites (LBMMS), Service de Biochimie et Biologie Moléculaire Grand Est, Hospices Civils de Lyon
Hypothesis
The study aims to evaluate a new tandem mass spectrometry method for sickle cell disease newborn screening.
Conclusion
The MS/MS Hemo kit is an effective method for sickle cell disease newborn screening, achieving near-100% sensitivity and specificity.
Supporting Evidence
- The MS/MS Hemo kit achieved 98.3% sensitivity and 99.9% specificity for sickle cell disease detection.
- Results from 1324 out of 1333 samples were consistent with HPLC and/or MALDI-TOF results.
- All clinically relevant cases were correctly classified in the study.
Takeaway
This study tested a new way to check if babies have sickle cell disease, and it worked really well, almost perfectly.
Methodology
The study used a dedicated MS/MS kit to analyze dried blood spots from newborns and compared results with established methods.
Limitations
The study's results should be confirmed in a larger cohort with more positive samples for sickle cell disease.
Participant Demographics
Newborns from the Hospices Civils de Lyon Maternity, targeting at-risk populations based on parental geographical origins.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website